Notícias e Atividades da Candel Therapeutics

Veja o organograma con seus 28 executivos principais

Biografias mais buscadas da Candel Therapeutics

• Paul-Peter Tak, Director, President and Chief Executive Officer
• Chris Martell, Director
• Edward Benz, Director

Recentes movimentos de executivos em Candel Therapeutics

• Allison Nylen antes Director, Finance, foi promovido a Corporate Controller  (Notícia publicada em 14 de janeiro de 2026).
• Kristin Kennedy, Corporate Controller, deixou a Companhia  (Notícia publicada em 14 de janeiro de 2026).
• Alex Cardoso antes Senior Director, Manufacturing, foi promovido a Vice President, Manufacturing  (Notícia publicada em 29 de setembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Candel Therapeutics.

Candel Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Candel Therapeutics

• Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer | Candel Therapeutics, Inc
• Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting | Candel Therapeutics, Inc
• Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Candel Therapeutics, Inc
• Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Candel Therapeutics, Inc
• Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors | Candel Therapeutics, Inc
• Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | Candel Therapeutics, Inc
• Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting | Candel Therapeutics, Inc
• Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Candel Therapeutics, Inc
• Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston | Candel Therapeutics, Inc
• Candel Therapeutics Announces Proposed $100 Million Public Offering | Candel Therapeutics, Inc
• View more press releases Close

Redes sociais sobre Candel Therapeutics

• Candel Therapeutics na Wikipedia, Google News e Yahoo Finance
• Candel Therapeutics na LinkedIn, X (Twitter) e YouTube